
Biomarkers

Applications and trends that are
revolutionising drug discovery
and development

August 2010



World Leaders in Health Industry Analysis

A partial view of a globe showing the Earth, with green continents and blue oceans, positioned in the bottom right corner of the page.

Biomarkers: Applications and trends that are revolutionising drug discovery and development

August 2010

ISBN: 978 1 85822 391 9

© Copyright 2010 Espicom Business Intelligence

All rights reserved. No part of this publication may be reproduced or used in any form or by any means graphic, electronic or mechanical, including photocopying, recording, taping or storage in information retrieval systems without the express permission of the publisher.

Every care has been taken to ensure that the information contained in this report is correct. The publisher accepts no liability for decisions made on the basis of information contained herein.

British Library Cataloguing in Publication Data.

A catalogue record for this report is available from the British Library.

Contents

The Business Implications	1
Chapter 1 - Biomarkers Defined	3
Executive Summary	4
Biomarkers defined	4
BIOMARKERS DEFINED	5
Table 1: Fit for purpose criteria	5
A Solution to Failing Pharma Productivity?	6
Figure 1: Pharma R&D activity & attrition rates (1995-2009)	6
Figure 2: Advantages of biomarker discovery in drug discovery & development	7
Potential Value of Biomarkers in Drug Discovery	8
Figure 3: Role of Biomarkers in drug discovery & development	8
Figure 4: Initiatives in biomarker discovery & development	9
Figure 5: Shift in attrition rates to early phase	10
New clinical diagnostic tools	11
Figure 6: Risk-based classification of IVDs	11
Conclusions	12
Chapter 2 - Regulatory Support: Implications for Pharma	13
Executive Summary	14
Regulatory support: implications for pharma	14
REGULATORY SUPPORT: IMPLICATIONS FOR PHARMA	15
Regulatory drivers	15
Where are we now?	16
Figure 7: Voluntary genomic data submissions: process & outcomes	16
Figure 8: Preliminary biomarker qualification process	17
EXPERT COMMENTARY: Spiros Vamvakas, MD,	18
What do new biomarker guidelines mean for the pharma industry?	20
Where are we going?	21
Conclusions	21
Chapter 3 - Challenges of Biomarker Discovery & Development	23
Executive Summary	24
Challenges of biomarker discovery & development	24
CHALLENGES OF BIOMARKER DISCOVERY & DEVELOPMENT	25
Figure 9: Multidisciplinary biomarker discovery, validation & qualification process	25
Biomarker discovery & validation	26
Figure 10: Multidisciplinary biomarker discovery – a collaborative effort	26
Technological challenges	27
Figure 11: Types of R&D biomarkers	27
Table 2: Biomarker sample types – advantages, limitations & recommendations	28
Sample collection & preparation	29
Table 3: Pre-analytical & analytical bias of samples & data	30
Multiplex Assays	30
Immunoassays	31
Mass Spectrometry	31
Figure 12: Protein Quantitation - MS based proteomics	31
Bioinformatics	32
Figure 13: Technological advances in proteomics increases data generation	32
EXPERT COMMENTARY: Dr Conrad Bessant	33

Systems biology	35
<i>Figure 14: Systems biology approach to biomarkers</i>	35
Conclusions	36
Chapter 4 - Applications of Biomarkers in Drug Discovery & Development	37
Executive Summary	38
Application of biomarkers in drug discovery & development	38
APPLICATION OF BIOMARKERS IN DRUG DISCOVERY & DEVELOPMENT	39
Overcoming bottlenecks in the R&D process	39
Biomarker Implementation in R&D	40
Translational Medicine	41
<i>Figure 15: Migration from traditional R&D model to translational R&D Model</i>	41
<i>Figure 16: Different phases of translational research</i>	42
Application of biomarkers in identifying new drug targets	43
Functional genomics	43
<i>Table 4: Drug discovery & development based on genomics targets</i>	43
Proteomics	44
Metabolomics	44
Application in improving safety and efficacy of new drugs	45
Case Study: Cellular Dynamics & stem cell derived iCell Cardiomyocytes	45
.....	45
EXPERT COMMENTARY: Dr Michael Merz, SAFE-T Consortium	46
Mechanism of action studies	48
Case Study: PBS-Bio real-time computer imaging technology	48
<i>Figure 17: PBS-Bio real-time computer imaging technology</i>	48
Conclusions	49
Chapter 5 - Applications of Biomarkers in the Clinic & Clinical Diagnostics	51
Executive Summary	52
Application of biomarkers in the clinic & clinical diagnostics	52
IMPLICATIONS & APPLICATIONS OF BIOMARKERS IN THE CLINIC	53
<i>Figure 18: Percent risk associated with different stages of drug development</i>	53
<i>Figure 19: Early drug development process</i>	54
Types of clinical biomarkers	55
Phase 0	55
Phase I/II	55
Phase III	56
Phase IV/V	56
.....	56
EXPERT COMMENTARY: Sam LaBrie, Ph.D.	57
Application of biomarkers in clinical drug development	59
Risk biomarkers	59
Patient enrichment	59
<i>Figure 20: Patient enrichment trial designs</i>	59
Response markers	60
Prognostic biomarkers	60
Prognostic imaging biomarkers	60
Surrogate biomarkers	61
<i>Figure 21: Relationship between biomarker and clinical outcome dependent on biomarker</i>	61
<i>Figure 22: Relationship between biomarker and clinical outcome independent of biomarker</i>	61
<i>Figure 23: Relationship between biomarker and clinical outcome on long term prognosis</i>	62
<i>Table 5: Biomarkers surrogate endpoints for safety</i>	62

Predictive biomarkers	63
Co-development of drugs and diagnostics	63
<i>Figure 24: Medical product (Rx)/Diagnostic (Dx) development models</i>	64
<i>Figure 25: Traditional medical product (Rx)/Diagnostic (Dx) development models</i>	64
Personalisation of medicine	65
<i>Table 6: Personalised medicine vs. traditional medicine</i>	65
<i>Table 7: Approved personalised medicines</i>	65
<i>Table 8: Personalised medicine market</i>	66
EXPERT COMMENTARY: Dr Scott Allocco, B.A.	67
Conclusions	70
Chapter 6 - Players, Alliances & Acquisitions	71
Executive Summary	72
Players, alliances & acquisitions	72
PLAYERS, ALLIANCES & ACQUISITIONS	73
Company activities at a glance	73
<i>Table 9: Leading biomarker discovery & development companies</i>	74
Alliances with market leaders	79
<i>Table 10: Summary of major pharmaceutical company biomarker alliances</i>	79
Therapeutic Activity	80
Cancer	80
<i>Table 11: Exploratory biomarkers for cancer</i>	81
Cardiovascular	81
<i>Table 12: Exploratory biomarkers for cardiovascular diseases</i>	81
CNS disorders	82
<i>Table 13: Exploratory biomarkers for CNS disorders</i>	82
Inflammatory disorders	83
<i>Table 14: Exploratory biomarkers of inflammatory diseases</i>	83
Infectious diseases	83
Alliance between biomarker-diagnostic companies	84
<i>Table 15: Key biomarker-diagnostic company alliances</i>	84
Alliances with academia & consortia	84
<i>Table 16: Key academia & consortia alliances</i>	84
Start-ups & acquisitions	85
Recent start-ups	85
Acquisitions	85
Conclusions	86
Chapter 7 - Outlook & Future of Biomarker Research	87
Executive Summary	88
Outlook & Future of Biomarker Research	88
OUTLOOK & FUTURE OF BIOMARKER RESEARCH	89
Market trends & forecasts	89
Increased collaboration	89
Increased numbers of qualified biomarkers & surrogate endpoints	90
Explore new therapeutic areas & rare diseases	90
Adoption of new technologies in biomarker identification & qualification	90
Increased number of companion-diagnostic programmes	91
Regulatory guidance & harmonisation	91
Financial investment in biomarker R&D	91
Biomarker impact near, mid and long-term	92
<i>Table 17: Factors affecting the impact of biomarkers on the industry over the near, mid & long-term</i>	92

Market Forecasts	93
<i>Table 18: Biomarker market forecast (US\$m)</i>	93
Ones to watch	94
<i>Table 19: Summary of ones to watch in biomarker R&D & commercialisation</i>	94
Overall Conclusions	96
Chapter 8 - Appendices, Glossary, Bibliography, Acknowledgements	97
Appendix 1	98
<i>Table 20: Recent biomarker alliances & developments in cancer</i>	98
Appendix 2	100
<i>Table 21: Recent biomarker alliances and developments in cardiovascular disease</i>	100
Appendix 3	100
<i>Table 22: Recent biomarker alliances & developments in CNS disorders</i>	100
Appendix 4	101
<i>Table 23: Recent biomarker alliances & developments in immune/ inflammatory disorders</i>	101
Acknowledgements	102
Glossary	103
Bibliography & Endnotes	105
Endnotes	106

List of Tables

Table 1: Fit for purpose criteria	5
Table 2: Biomarker sample types – advantages, limitations & recommendations.....	28
Table 3: Pre-analytical & analytical bias of samples & data.....	30
Table 4: Drug discovery & development based on genomics targets.....	43
Table 5: Biomarkers surrogate endpoints for safety	62
Table 6: Personalised medicine vs. traditional medicine.....	65
Table 7: Approved personalised medicines	65
Table 8: Personalised medicine market.....	66
Table 9: Leading biomarker discovery & development companies.....	74
Table 10: Summary of major pharmaceutical company biomarker alliances.....	79
Table 11: Exploratory biomarkers for cancer	81
Table 12: Exploratory biomarkers for cardiovascular diseases	81
Table 13: Exploratory biomarkers for CNS disorders.....	82
Table 14: Exploratory biomarkers of inflammatory diseases	83
Table 15: Key biomarker–diagnostic company alliances.....	84
Table 16: Key academia & consortia alliances.....	84
Table 17: Factors affecting the impact of biomarkers on the industry over the near, mid & long-term.....	92
Table 18: Biomarker market forecast (US\$m)	93
Table 19: Summary of ones to watch in biomarker R&D & commercialisation	94
Table 20: Recent biomarker alliances & developments in cancer	98
Table 21: Recent biomarker alliances and developments in cardiovascular disease	100
Table 22: Recent biomarker alliances & developments in CNS disorders	100
Table 23: Recent biomarker alliances & developments in immune/ inflammatory disorders	101

List of Charts

Figure 1: Pharma R&D activity & attrition rates (1995-2009)	6
Figure 2: Advantages of biomarker discovery in drug discovery & development	7
Figure 3: Role of Biomarkers in drug discovery & development	8
Figure 4: Initiatives in biomarker discovery & development	9
Figure 5: Shift in attrition rates to early phase.....	10
Figure 6: Risk-based classification of IVDs.....	11
Figure 7: Voluntary genomic data submissions: process & outcomes	16
Figure 8: Preliminary biomarker qualification process.....	17
Figure 9: Multidisciplinary biomarker discovery, validation & qualification process	25
Figure 10: Multidisciplinary biomarker discovery – a collaborative effort.....	26
Figure 11: Types of R&D biomarkers.....	27
Figure 12: Protein Quantitation - MS based proteomics	31
Figure 13: Technological advances in proteomics increases data generation.....	32
Figure 14: Systems biology approach to biomarkers	35
Figure 15: Migration from traditional R&D model to translational R&D Model	41
Figure 16: Different phases of translational research	42
Figure 17: PBS-Bio real-time computer imaging technology	48
Figure 18: Percent risk associated with different stages of drug development.....	53
Figure 19: Early drug development process	54
Figure 20: Patient enrichment trial designs	59
Figure 21: Relationship between biomarker and clinical outcome dependent on biomarker.....	61
Figure 22: Relationship between biomarker and clinical outcome independent of biomarker	61
Figure 23: Relationship between biomarker and clinical outcome on long term prognosis	62
Figure 24: Medical product (Rx)/Diagnostic (Dx) development models	64
Figure 25: Traditional medical product (Rx)/Diagnostic (Dx) development models	64